Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone
Status:
Terminated
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at the effects of cabozantinib on castrate-resistant
prostate cancer metastatic (cancer that has spread to other parts of the body) to the bone
and to learn about any side effects caused by taking cabozantinib.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center